Inclusion Criteria:  Aged ≥18; Essential mild to moderate hypertension (office systolic blood pressure (SBP) ≥ 140 and < 180mmHg in untreated patients or patients with taking single antihypertensive drugs (not including single-pill combination))； Echocardiographic diagnosis of LVH，LVMI: male≥115g/m2, female≥ 95g/m2; Ability to understand the study requirements and provide informed consent.  Exclusion Criteria:  Hypersensitivity history to any study drug or similar drug (ARB, ACEI, neprilysin inhibitor； Severe renal insufficiency (eGFR < 30 mL/min/1.73m2); Hyperkalemia (serum potassium > 5mmol/L); Active liver disease or hepatic insufficiency (AST or ALT > 3 times upper limit of normal); History of malignancy over the past 5 years; Severe disease patients with life expectancy of < 1 year; Previous or current diagnosis of heart failure; Stroke or myocardial infarction within 6 months; Previous or current atrial fibrillation, frequent ventricular premature beats, supraventricular tachycardia; Patients who are receiving other study drugs or study medical devices; Pregnant or lactating women; Other circumstances that patients are not appropriate for the study upon the investigator's judgment.